Glaxosmithkline plc (GSK) and Avalon Ventures shook hands on the seventh deal in their 2-year-old build-to-buy translational medicine collaboration by establishing Iron Horse Therapeutics Inc., which will seek to advance treatments for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, by modulating the activity of the protein EphA4.